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Abstract
Background: Omega-3 long chain-polyunsaturated fatty acids (LC-PUFAs)–docosahexaenoic acid (DHA), docosapentaenoic
acid (DPA) and eicosapentaenoic acid (EPA)– and omega-6 LC-PUFA arachidonic acid (ARA), are essential for
optimum physical and mental development in children. Prior to this study, the blood omega-3 LC-PUFA levels were
unknown in Zimbabwean children, particularly in those aged 7–9 years, despite the documented benefits of LC-PUFAs.
Documentation of the LC-PUFA levels in this age group would help determine whether interventions, such as
fortification, are necessary. This study aimed to determine dried whole blood spot omega-3 and omega-6 LC-PUFA
levels and LC-PUFA reference intervals among a selected group of Zimbabwean children aged 7–9 years old.
Methods: We conducted a cross sectional study from September 2011 to August 2012 on a cohort of peri-urban,
Zimbabwean children aged 7–9 years. The children were born to mothers enrolled at late pregnancy into an HIV
prevention program between 2002 and 2004. Dried whole blood spots were sampled on butylated hydroxytoluene
antioxidant impregnated filter papers and dried. LC-PUFAs were quantified using gas liquid chromatography.
Differences in LC-PUFAs between groups were compared using the Kruskal Wallis test and reference intervals
determined using non-parametric statistical methods.
Results: LC-PUFAs levels were determined in 297 Zimbabwean children of whom 170 (57.2 %) were girls. The study
determined that LC-PUFAs (wt/wt) ranges were EPA 0.06–0.55 %, DPA 0.38–1.98 %, DHA 1.13–3.52 %, ARA 5.58–14.64 %
and ARA: EPA ratio 15.47–1633.33. Sixteen participants had omega-3 LC-PUFAs levels below the determined reference
intervals, while 18 had higher omega-6 LC-PUFAs. The study did not show gender differences in omega-3 and
omega-6 LC-PUFAs levels (all p > 0.05). EPA was significantly higher in the 8 year age group compared to those aged 7
and 9 years (median; 0.20 vs 0.17 vs 0.18, respectively, p = 0.049). ARA: EPA ratio was significantly higher in the 7 year
age group compared to those aged 8 and 9 years (median; 64.38 vs 56.43 vs 55.87 respectively, p = 0.014).
Conclusions: In this cohort of children, lower EPA levels and higher ARA: EPA ratios were observed compared to those
reported in apparently healthy children elsewhere. The high ARA: EPA ratios might increase the vulnerability of these
children to inflammatory pathologies. Identification and incorporation into diet of locally produced foodstuffs rich in
omega-3 LC-PUFAs is recommended as well as advocating for dietary supplementation with omega-3 fish oils and
algae based oils.
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Background
Omega-3 long chain-polyunsaturated fatty acids (LC-
PUFAs)—docosahexaenoic acid (DHA), eicosapentaenoic
acid (EPA) and docosapentaenoic acid (DPA)—are essential
for growth, development and general health [1]. Omega-6
LC-PUFA arachidonic acid (ARA) is essential for brain
development [2]. DHA is especially critical for optimal
brain [2], cognitive [3] and behavior development. EPA is a
precursor of anti-inflammatory eicosanoids (prostaglandins
(3 series), leukotrienes (5 series) and thromboxanes
(TXA3)) [4], and adequate intake of EPA is closely related
to positive immunological [5], inflammatory [6] and meta-
bolic [7] outcomes. DPA has been reported to have benefi-
cial effects which include inhibiting platelet aggregation,
stimulating endothelial cell migration and regulating gene
expression [8]. Though Arachidonic acid (ARA) is a
precursor of pro-inflammatory eicosanoids (prostaglandins
(2 series), leukotrienes (4 series) and thromboxanes(TXA2))
[4]; it produces some metabolites that are required for
systemic homeostasis [9]. ARA and its metabolite lipoxin
A4 have been shown to function as endogenous anti-
diabetic molecules [10]. ARA together with LC-PUFAs and
their anti-inflammatory products: lipoxins, resolvins,
protectins and maresins suppress production of pro-
inflammatory eicosanoids, limit inflammation, enhance
wound healing, resolve inflammation thus restoring normal
cellular, tissue and organ function [10].
Supplementation with omega-3 LC-PUFAs in cardio-
vascular diseases (CVD) [11], diabetes mellitus [12],
hypertension [13], sickle cell anemia [14], inborn errors
of metabolism [15, 16], non-alcoholic fatty liver disease
[17, 18], attention-defect/hyperactivity disorder [19]
autism [20] and asthma [21] has been reported to
prevent or alleviate symptoms in children, though other
studies have reported conflicting results [22–25].
The above disorders are due to deficiencies in omega-
3 fatty acids. Deficiencies in omega-3 fatty acids may
result from factors that affect availability of omega-3
LC-PUFAs and influence the metabolism of essential
fatty acids (EFA) to LC-PUFAs. These include, imbalances
in metabolic pathways [26], genetics [27], imbalances in
ARA: EPA ratios [28] and sex hormones [29]. The imbal-
ances in the metabolic pathway may result from linoleic
acid (LA) competing with α-linolenic acid (ALA) for the
endogenous conversion of ALA to the long chain deriva-
tives EPA and DHA and also inhibition of incorporation
of DHA and EPA into tissues [26]. Therefore high levels
of LA in the diet result in low ALA and low omega-3 LC-
PUFA levels. This in turn affects the omega-6: omega-3
(ARA: EPA) ratios which are critical in human health
outcomes [20, 28]. The high levels of LA lead to increased
activity of the ARA metabolic pathway [4], which has
deleterious effects such as neurological and neurodevelop-
mental disorders [30]. High concentrations of ARA
compete with EPA for incorporation into cell membrane
phospholipid leading to high ARA: EPA ratios [28]. The
low omega-3 LC-PUFA levels can be due to deficiencies
and defects in the Δ6 or Δ5 desaturase enzyme [31] or
mutations in the fatty acid desaturase (FADS) gene [27].
Protein malnutrition, carnitine and α-tocopherol enzyme
deficiency as well as excess oxygen free radical production
in chronic diseases also affect LC-PUFA availability [32].
Oestrogen and testosterone, have been reported to affect
EFA metabolism hence availability of long chain me-
tabolites, leading to higher levels in females compared
to males [29]. The conversion of EFA into their long
chain metabolites is stimulated by oestrogen and
inhibited by testosterone [29].
Despite the reported benefits of omega-3 LC-PUFAs
in children, most studies demonstrating the nutritional
importance of omega-3 LC-PUFAs in children have
been carried out in developed countries [2, 3, 11–13],
[15–17, 19, 21] with a limited number of studies on
African children [14, 33–35]. In most of sub-Saharan
Africa healthcare facilities, omega-3 LC-PUFA levels
are not on clinical laboratories test menus because
the laboratories lack the expertise and technology to
perform the tests [36]. In the past the assessment of
omega-3 LC-PUFAs has been hindered by difficult
methodology [37] and sample instability [38, 39].
Analysis has since been revolutionized by the use of
minimally invasive dried blood spots (DBS) [40],
which allow the estimation of fatty acid composition
of red blood cells and plasma phospholipids that are
more reflective of the nutritional status [41]. To date,
only a few studies have developed protocols for test-
ing LC-PUFAs in DBS [37–40, 42], with none being
carried out in Africa.
In Southern Africa, a region with high prevalence of
childhood infectious diseases [43], the levels of omega-3
LC-PUFAs in children are unknown, except in South
Africa where the positive effects of omega-3 LC-PUFA
supplementation on cognitive development were re-
ported in children aged between 6 and 11 years [33–35].
There is paucity of data on omega-3 LC-PUFA levels in
the rest of African countries, including Zimbabwe, espe-
cially in children whose adequate intake of LC-PUFAs
should be ensured for cognitive development and other
positive health outcomes [44].
Monitoring of fatty acid levels and results interpret-
ation in individual patients or in populations require
availability of reference intervals obtained from appar-
ently healthy individuals [45]. Fatty acids reference
intervals have been established for glycerophospholipids
in German children aged 2 and 6 years, for whole blood
in apparently healthy European children aged 3–8 years
[46] and in apparently healthy Spanish children who
were on a normal diet for their age elsewhere [15] but
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these may not be transferable to a different population.
However, scanty studies have been done in low income
settings particularly in African children and none in
Zimbabwe. At present no reference intervals for LC-
PUFAs have been established in these settings.
In this study, the levels of omega-3 LC-PUFAs were
determined in Zimbabwean children aged between 7 and
9 years using DBS and reference intervals for LC-PUFAs
were determined. The LC-PUFAs were compared
between groups by gender and by age.
Methods
Study design and setting
From September 2011 to August 2012 we conducted a
cross sectional study at three peri-urban primary health
care clinics around Harare, the capital city of Zimbabwe.
Children aged 7 to 9 years born between 2002 and 2004
to a cohort of mothers previously recruited at late
pregnancy from a national HIV prevention of mother to
child transmission (PMTCT) program [47], were invited
to participate in the study. These children were also
eligible if they had no major chronic diseases. Children
who were not born to the specified cohort, or who were
siblings to the original cohort or whose care givers
declined to allow them to take part in the study were
excluded as well as those who were HIV-infected, those
with inflammatory pathologies and other chronic
diseases like diabetes mellitus that may influence the
fatty acid composition. All the children were tested for
HIV infection at birth, at 6 weeks and subsequently after
18 months.
The study protocol and consent forms were approved
by the Joint Research Ethics Committee: (JREC/170/12),
and the Medical Research Council of Zimbabwe:
(MRCZ/B/359). The consent forms were also approved
by the Norwegian Research Ethics Committee. Permission
to ship participant samples abroad for laboratory analysis
was granted by the Research Council of Zimbabwe. Writ-
ten informed consent to participate in the study and for
long term specimen storage and shipping was obtained
from parents or legal guardians and written assent was
also obtained from all the children.
Blood collection
After cleaning, warming and punching a fingertip with
an automatic lancing device equipped with a sterile lan-
cet, a drop of non-fasting capillary whole blood sample
(~50 μl) from each participant was spotted onto each of
the four pre-defined circles on a Whatman 903 (Lot
number 6833909/82) filter paper cards (GE Healthcare,
UK), which was impregnated with anti-oxidant (butyl-
ated hydroxytoluene (BHT; 50 mg/100 ml in ethanol)
(Sigma Aldrich Limited, Gillingham Dorset, UK)), for
the determination of omega-3 LC-PUFA levels [39].
BHT in Ethanol was prepared at a concentration of
0.05 %. Each spot on the Whatman 903 filter paper card
to be used for blood collection was impregnated with
the BHT in ethanol solution, by fully covering each col-
lection spot with the solution (by adding two drops).
The cards were air-dried for an hour and placed in a
sealed polyethylene bag overnight. The filter paper cards
were treated with the BHT antioxidant to prevent the
polyunsaturated fatty acids losses due to oxidation. The
samples were air-dried for 3 h and stored at −25 °C in a zip
lock foil paper (Whatman, Maidstone/Banbury UK) with a
desiccant (Whatman, Maidstone/Banbury UK) [39].
Preparation of fatty acid methyl esters (FAMEs) in DBS,
extraction, purification and detection
Fatty acid extraction and detection
Analysis of PUFAs was carried out at the Nutrition
Group Laboratories, Institute of Aquaculture at the Uni-
versity of Stirling, Scotland UK, using a fingertip rapid
method that was evaluated by Marangoni et al. [40], and
validated by Bell et al. [39]. One DBS circle (per sample),
one DBS circle (internal standard), and one DBS circle
(control) were cut out from the main DBS filter paper
cards using a pair of scissors and forceps and were
placed each in a pre-labeled 10 ml screw cap vial which
was loaded on the CTC-PAL machine carousel. At the
beginning and end of each batch of samples or once a
week, a marinol FAME secondary reference material and
the Supelco 37 controls were run simultaneously with
each run/batch of participants to ensure reproducibility
of the known control values. The fatty acids from
participants’ samples, standards and quality control sam-
ples were transesterified to fatty acid methyl esters
(FAMEs) using 1.25 M HCL/Methanol and incubated in
dry heating block at 70 °C for 1 h [39]. This was a modi-
fication of the one step direct transmethylation method
described by Lepage and Roy [48]. The FAMEs were ex-
tracted into iso-hexane (Fisher Scientific, Loughborough,
UK) and precipitated with saturated potassium chloride
(Fisher Scientific, Loughborough, UK) before purifica-
tion [39]. Purification was done by passing the extract
through a preconditioned solid phase extraction (SPE)
cartridge (Clean-Up Extraction Columns, UCT, Bristol,
USA) (prewashed with iso-hexane) and eluted with iso-
hexane—diethyl ether (95:5 v/v) (Fisher Scientific,
Loughborough, UK) [39]. The FAME extracts were dried
under nitrogen (BOC Gases, Guildford, UK) using a
nitrogen evaporator (N-EVAP™ 111, Organomation As-
sociates, Berlin USA) at room temperature, re-dissolved
in 0.2 ml iso-hexane and placed in an autosampler vial
(Chromacol, Herts, UK) prior to gas liquid chromatog-
raphy (GLC) (Thermo Fisher Trace, Hertfordshire UK)
analysis [39]. The stability of the fatty acid analytes in
whole wet blood and in the dried whole blood samples
Mashavave et al. BMC Clinical Pathology  (2016) 16:14 Page 3 of 10
at different temperatures (room temperature, 4 and
−20 °C) and at different times periods ((3 h post drying)
and subsequent samples were removed for analysis after
48 h, 7 days, 14 days and 28 days in storage) was investi-
gated by Bell et al. [39].
The GLC was calibrated using duplicate injections of
standard mixtures of known composition (Supelco AOCS
No. 37 standards containing 14:0 to 22:6n-3). A second
standard, a Supelco custom mix containing 14:0, 16:0,
16:In-7, 18:0, 18:In-7, 18:2n-6, 10:0, 10:5n-3, 22:In-9,
22:5n-3 and 22-6n-3, was used to check calibration and
replication by making three consecutive analyses. FAMEs
(1 μl) were injected, separated and quantified by GLC
using a 60 m × 0.32 mm × 0.25 μm film thick capillary
column (ZB Wax; Phenomenex, Macclesfield, Cheshire,
UK). Hydrogen gas (BOC Gases, Guildford, UK) was used
as a carrier gas at a flow rate of 4.0 ml/min and the
temperature program was from 50 to 150 °C at 40 °C/min
then to 195 °C at 2 °C/min and finally to 215 °C at
0.5 °C/min [39]. The FAMEs were detected by a flame
ionization detector. The FAMEs were compared to well-
characterized in-house standards as well as commercial
FAME mixtures (Supelco™ 37 FAME mix; Sigma Aldrich
Limited, Gillingham Dorset, UK). Fatty acids ranging from
C14:0 to C22:6 carbons were detected. The fatty acid data
was collected from the GLC and processed using the
Chromocard software computer package for Windows
(version 2.1) (Thermoquest Italia S. p. A., Milan, Italy).
The FAMEs results were expressed as percent weight of
individual fatty acids in total fatty acids (% weight/weight
(% wt/wt)). Precision and coefficient of variation were
done by Bell et al. using the same analytical method, on
same instrumentation and in the same establishment as
the work published in this manuscript.
The total omega-6 LC-PUFAs measured included;
Dihomo-gamma-linolenic acid (DGLA), ARA and
Docosapentaenoic acid (DPA) (n-6) whereas the total
omega-3 LC-PUFAs included; EPA, DPA (n-3) and
DHA. Omega-6 LC-PUFAs were included in the results
since they compete with omega-3 LC-PUFAs for the
same enzymes for desaturation. The results of EPA, DPA
(n-3), DHA, ARA, and the calculated total omega-3
PUFAs, total omega-3 LC-PUFA: total omega LC-
PUFAs, ARA: EPA, total omega-6 LC-PUFA: total
omega-3 LC-PUFA ratios were selected for data analysis.
Statistical analysis
Participants’ characteristics were summarized using
percentages for categorical variables and median [inter-
quartile ranges (IQR)] for continuous non-normal
variables. Differences in median omega-3 LC-PUFAs by
age group and by gender were compared using the
Kruskal-Wallis test. To account for multiple compari-
sons, we applied the Bonferroni correction which lowers
(adjust) the α value (type1 error) to account for the
number of comparisons being performed simultan-
eously, thereby avoiding a lot of spurious positives. Non-
parametric statistical methods from Reference Value
Advisor v1.3 [49] were used to determine the central
95 % reference interval limits, with the lower limit
defined as the 2.5 percentile and the upper limit defined
as the 97.5 percentile, together with the 90 % confidence
intervals (CI) of the distribution of omega-3 LC-PUFAs.
For all statistical comparisons α (p value) was set at 0.05.
Data entry and analysis was conducted using Statistical
Package for Social Scientists (SPSS, New York, USA).
Results
A total of 319 of the available children from the original
cohort participated in the study. Of these children, one
had a DBS collected on a non BHT treated filter paper
and 21 (6.6 %) were HIV-infected. Those who were HIV
infected were all excluded from further analysis. Of the
remaining 297, the median age (range) was 9 (7–9) years
and 170 (57.2 %) were girls (Table 1).
Distribution and comparison of LC-PUFA levels
Sixteen (5.39 %) of the children had EPA, DPAn-3, DHA
levels that were below the determined reference intervals
and 18 (6.06 %) had ARA levels, ARA: EPA and total
omega-6 PUFA: Total omega-3 PUFA ratios that were
above the determined reference intervals. The LC-PUFAs
(% wt/wt) ranges were as follows: EPA 0.06–0.55 %, DPA
0.38–1.98 %, DHA 1.13–3.52 %, ARA 5.58–14.64 % and
ARA: EPA ratio 15.47–1633.33 (Table 2).
The median LC-PUFA levels between boys and girls
were not significantly different (p > 0.05).
EPA levels were significantly elevated in the 8 year age
group compared to those aged 7 and 9 years (0.17 vs
0.20 vs 0.18, respectively, p = 0.049). The median ARA:
EPA ratio was significantly elevated in the 7 year age
group compared to the other age groups (p = 0.014)
(Table 2). Distribution of median ARA: EPA ratio was
significantly different between age groups after being
corrected using the Bonferoni test (Fig. 1).
Table 1 Age and gender of the children
Variable Frequency n = 297
Gender of the children
Boys 127 (42.8 %)
Girls 170 (57.2 %)
Children age group (years)
7 21 (7.1 %)
8 93 (31.3 %)
9 183 (61.6 %)
p-values calculated using Bonferroni test. Statistically Significance (p < 0.05)
(2-tailed)
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Table 2 Distribution of median (IQR) LC-PUFA levels (% wt/wt) by gender and age group of 297 Zimbabwean children
Variables LC-PUFAs (% wt/wt)




ARA: EPA Total n-6 PUFA:
Total n-3 PUFA
Median (IQR) (n = 297) 0.18 (0.15–0.23) 0.79 (0.70-0.89) 2.14 (1.87-2.42) 10.62 (9.77–11.38) 3.13 (2.83–3.49) 18.42 (17.10–19.92) 57.47 (44.72–72.24) 10.82 (9.83–11.79)
Mean (SD) (n = 297) 0.20 (0.071) 0.81 (0.17) 2.15 (0.40) 10.56 (1.26) 3.55 (0.53) 18.11 (2.27) 61.31 (23.64) 10.91 (1.62)
Range All (n = 297) 0.06–0.55 0.38–0.198 1.13–3.52 5.58–14.64 1.73–5.95 13.34–28.11 15.47–163-33 5.94–16.03
Children’s gender
median IQR)
Boys (n = 127) 0.19 (0.15–0.23) 0.81 (0.72–0.91) 2.11 (1.91–2.46) 10.55 (9.80–11.32) 3.25 (2.62–3.42) 18.38 (17.32–19.94) 57.16 (45.24–71.82) 10.71 (9.78–11.68)
Girls (n = 170) 0.18 (0.15–0.24) 0.78 (0.70–0.89) 2.15 (1.84–2.36) 10.67 (9.73–11.46) 3.10 (2.82–3.47) 18.44 (16.94–19.89) 57.72 (44.09–72.91) 10.95 (9.88–11.97)
Children’s Age group
median (IQR)
(7) (n = 21) 0.17 (0.13–0.18) 0.78 (0.74–0.86) 2.27 (2.03–2.48) 10.89 (10.68–11.75) 3.18 (2.92–3.53) 18.20 (16.69–19.52) 64.38 (59.71–91.04) 10.60 (9.93–11.89)
(8) (n = 93) 0.20 (0.16–0.24) 0.81 (0.70–0.93) 2.16 (1.93–2.51) 10.63 (9.61–11.39) 3.18 (2.87–3.57) 18.64 (17.35–20.18) 56.43 (41.39–72.02) 10.55 (9.68–11.45)
(9) (n = 183) 0.18 (0.15–0.23) 0.79 (0.70–0.89) 2.10 (1.83–2.35) 10.48 (9.76–11.35) 3.09 (2.80–3.40) 18.34 (16.94–19.88) 55.87 (44.90–70.64) 10.94 (9.87-12.01)
p-values P = 0 .049a P = .014a
p-values calculated using Kruskal Wallis Test Asterisks: Significance tests: aStatistically Significance (p < 0.05) (2-tailed)
Key to Tables 2-3
EPA (20:5n-3): Eicosapentaenoic acid;
DPA (22:5n-3): Docosapentaenoic acid (n-3);
DHA (22:6n-3): Docosahexaenoic acid 
ARA (20:4n-6) Arachidonic acid
Total Omega-3 PUFA (EPA + DPA + DHA)
Total Omega-6 PUFA (DGLA + ARA + AA + DPA (n-6))
Omgea-3 LC-PUFA: Total LC-PUFA [(EPA + DPA + DHA)]: [(DGLA + ARA + AA + DPA (n-6)) + (EPA + DPA + DHA)]
Total n-6 PUFA: Total n-3 PUFA (DGLA + ARA + AA + DPA (n-6)): (EPA + DPA + DHA)
ARA: EPA Arachidonic acid: Eicosapentaenoic acid
DGLA (20:3n-6) Dihomo-gamma-linolenic acid
AA (22:4n-6) Adrenic acid












Reference intervals of LC-PUFAs
Reference intervals were determined for the 297 7–9
year old Zimbabwean children. Five children (1.7 %) had
EPA levels below the 2.5 percentile (0.09 % wt/wt), while
6 (2.0 %) had EPA levels above the 97.5 percentile
(0.37 % wt/wt). Five children (1.7 %) had DPA levels
below the 2.5 percentile (0.53 % wt/wt) and 6 (2.0 %)
were above the 97.5 percentile (1.15 % wt/wt). Six chil-
dren (2.0 %) had DHA levels below the 2.5 percentile
(1.35 % wt/wt) and 6 (2.0 %) were above the 97.5 per-
centile (2.93 % wt/wt). Six children (2.0 %) had ARA
levels below the 2.5 percentile (7.85 % wt/wt) and 7
(2.4 %) were above the 97.5 percentile (12.92 % wt/wt).
The LC-PUFA reference intervals with 90 % CI as deter-
mined from the results of the 7–9 year old Zimbabwean
children are shown in Table 3.
Discussion
To our knowledge, this is the first study to report blood
levels of omega-3 and omega-6 LC-PUFAs and to
determine LC-PUFA reference intervals in 7–9 year old
Zimbabwean children.
The levels for omega-3 LC-PUFAs (EPA, DPAn-3 and
DHA) of the children in this study were strikingly low,
while those of omega-6 LC-PUFA (ARA) were surpris-
ingly high compared to the determined reference
intervals and to the results obtained from a UK study on
similar age groups and biomarker [42] (EPA 0.20 v 0.56,
DPAn-3 0.81 v 1.03, DHA 2.15 v 1.9, ARA 10.56 v 8.17).
Generally, these children had very low omega-3 PUFAs
and very high saturated fats, monounsaturated and
omega-6 fatty acids. The essential omega-3 fatty acid, α-
linolenic acid, which is the precursor of the omega-3
LC-PUFAs (EPA, DPA and DHA), mainly found in
seeds, nuts and some vegetable oils, was also low in the
children under study (median level 0.38 % wt/wt)
compared to results obtained from a study on similar
age groups and biomarker [42]. The highest EPA value
Fig. 1 ARA: EPA ratio between ages groups of 297 Zimbabwean children
p-values calculated using Bonferroni test. Statistically Significance
(p<0.05) (2-tailed)
Table 3 Reference Intervals of LC-PUFAs (% wt/wt) in Zimbabwean children aged 7–9 years
LC-PUFAs (% wt/wt) Median (IQR)
(n = 297)
Reference Intervals 7–9 years old n = 297
2.5th Percentile (90 % CI) 97.5th Percentile (90 % CI)
Omega-3 fatty acids
ALA (18:3n-3) 0.38 (0.29–0.47) 0.17 (0.16 0.20) 0.73 (0.67 0.86)
EPA (20:5n-3) 0.18 (0.15–0.23) 0.09 (0.08 0.10) 0.37 (0.33 0.45)
DPA (22:5n-3) 0.79 (0.70–0.89) 0.53 (0.49 0.57) 1.15 (1.07 1.26)
DHA (22:6n-3) 2.14 (1.87–2.42) 1.35 (1.26 1.46) 2.93 (2.86 3.16)
Total n-3 PUFA 3.55 (3.22–3.87) 2.55 (2.39 2.64) 4.64 (4.45 5.10)
Omega-6 fatty acids
ARA (20:4n-6) 10.62 (9.77–11.38) 7.85 (6.86 8.32) 12.92 (12.57 13.55)
Total n-6 PUFA 38.10 (36.72–39.39) 33.18 (31.72 33.91) 41.74 (41.14 42.41)
Other fatty acids
Total saturated 38.55 (37.45–39.74) 35.82 (35.51 36.12) 42. 71 (41.50 43.18)
Total monounsaturated 16.20 (15.33–17.61) 13.75 (13.37 14.07) 21.39 (20.23 22.04)
Total DMA 3.29 (3.00–3.62) 2.44 (1.99 2.62) 4.15 (3.96 4.38)
ARA: EPA 57.47 (44.72–72.24) 26.51 (21.58 28.26) 110.83 (104.50 144.63)
% n-3LC-PUFA: Total LC-PUFA 18.42 (17.10 19.92) 14.54 (14.06 14.98) 24.56 (23.00 26.34)
Total n-3 LC-PUFA 3.13 (2.83–3.49) 2.14 (1.98 2.28) 4.29 (4.03 4.71)
Total n-6 PUFA: Total n-3 PUFA ratio 10.82 (9.83–11.79) 7.91 (7.42 8.48) 14.48 (14.04 15.13)
Fatty Acids Acronyms: ALA “α-Linolenic acid”, EPA “Eicosapentaenoic acid”, DPA “Docosapentaenoic acid”, ARA Arachidonic acid”, DMA Dimethylacetal
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obtained in this study of 0.55 % wt/wt was lower than
the mean values obtained from a study on similar age
groups and biomarker [42]. Results of the present study
also demonstrated the lowest EPA value of 0.06 % wt/wt
reported in apparently healthy children compared to re-
sults obtained from a study on similar age groups and
biomarker [42]. This might be a reflection of the differ-
ent geographical backgrounds, diet and genetic make-up
of the children in the different studies.
The low EPA and high ARA levels are of health concern
because they lead to very high ARA: EPA ratios, which are
pro-inflammatory, and to very high total omega-6 PUFA:
total omega-3 PUFA ratios [30]. The high ratios observed
in this study reflect possible imbalances in the dietary in-
take of omega-6 and omega-3 rich foods. The imbalances
could be as a result of contemporary changes in human nu-
trition caused by increased consumption of diets rich in sat-
urated fats (rich in beef), monounsaturated and omega-6
fatty acids including the use of cooking oils, vegetable oils
and bread spreads rich in omega-6 PUFAs, accompanied by
a decreased intake of omega-3 PUFA-rich foods [50]. Defi-
ciencies in DHA exposes children between the ages of 7
and 9 to impaired brain development during the 7–9 year
old “Brain Spurt” [44], possibly leading to compromised
intellectual development, academic performance, low verbal
learning ability, memory and learning difficulties [33, 34].
The LC-PUFA levels of all parameters except DHA
were lower in the present study compared to the expected
values from the University of Stirling Aquaculture labora-
tory [39] that used the same method of analysis and
sample type (DBS) as the present study (EPA 0.20 v 0.91,
DPA 0.81 v 2.47, DHA 2.15 v 2.47, ARA 10.56 v 13.88).
The median EPA level in the present study was simi-
lar to that obtained by Mohammed et al. on pregnant
Zimbabwean black women [36], indicating a general
view of the dietary intake of foods poor in omega-3
LC-PUFAs and α-linolenic acid in the population.
Our findings of no differences by gender in median LC-
PUFAs levels were in agreement with those of Glaser et al.
on a paediatric population [45]. However, another study on
a paediatric population reported a more pronounced low
omega-3 and omega-6 LC-PUFA status in girls than boys
[42], while another study reported slightly higher omega-6
ARA in boys than in girls [46]. Yet another study, reported
that sex hormones (testosterone and oestrogen) influence
the enzymatic synthesis of LC-PUFAs, leading to gender re-
lated differences in LC-PUFA status with higher levels oc-
curring in adult females [29]. The reason for the lack of
gender differences in LC-PUFA levels observed in this study
was perhaps due to the younger age of the participants.
The observed differences in median EPA and ARA:
EPA ratio across and between the children’s age groups
is probably due to differences in dietary content. The
7 year old children had lower EPA and higher ARA
values leading to high ARA: EPA ratio. The low EPA
values observed in the children understudy are however
constrained by the lower sample size in this particular
age group; hence the results should be interpreted with
caution. These findings were similar to UK study on
similar age groups and biomarker [42] and also similar
to the study with European children though with no age
dependence for ARA [46]. An Italian study with differ-
ences in fatty acids by age groups concluded that the dif-
ferences resulted either from lower intakes or the rates
of utilization and resulting physiological requirements
which are higher in younger age groups compared to
older age groups [51].
The study also determined DBS LC-PUFA reference
intervals for the apparently healthy 7–9 year old Zim-
babwean children. However, these DBS LC-PUFA refer-
ence intervals cannot be generalised to the rest of the
population since the LC-PUFA results were from
children from a select group born to a cohort residing in
a peri-urban setting, which did not include rural and
urban children. The determined LC-PUFA reference in-
tervals were not comparable to those of three other
studies which determined LC-PUFA reference intervals
perhaps due to methodological differences [15, 45, 46].
Our results showed generally low values across the
omega-3 LC-PUFA range. The levels of these LC-PUFAs
could be improved by identifying and encouraging the
intake of locally available omega-3 LC-PUFA rich foods.
Supplementation with EPA and DHA omega-3 fish oils
and algae based oils to balance ARA levels is recom-
mended in the children since low omega-3 LC-PUFA
levels are recognized confounders of general health.
Limited intake of ARA-rich foods is also recommended
if the desirable total omega-6 PUFA: total omega-3
PUFA ratio of 1–4:1 [6] is to be achieved. There is need
for a public awareness campaign on food sources rich in
omega-3 LC-PUFAs and the benefits of omega-3 LC-
PUFAs throughout life. We recommend further studies
on children under the age of 5 years and inclusion of
children from rural and urban Zimbabwe to ascertain
their omega-3 LC-PUFA levels. Results from such
studies could be used as the basis for establishing
reference intervals that can be generalized to the
whole Zimbabwean paediatric population, as well as
the basis for food fortification and the implementa-
tion of omega-3 LC-PUFA supplementation policies.
The study has a number of limitations. Firstly no
dietary intake assessment was done during specimen
collection to ascertain the practices that could explain
the low omega-3 LC-PUFA levels, hence, the causes of
low omega-3 LC-PUFA levels are assumption based.
Secondly, the determined reference intervals are limited
to the children born to the specified cohort as a limited
age group was used for this study. The study population
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was also restricted to children in a peri-urban setting that
may not be truly reflective of the Zimbabwean population.
The determined DBS reference intervals could also not be
compared to those from other populations because of
analytical method differences [15, 45, 46]. Lastly, the three
age groups were unequal and this could distort the
distribution of omega-3 LC-PUFAs findings by age.
Conclusion
Nevertheless, this is an important study that observed
very low EPA levels and very high ARA: EPA and total
omega-6 PUFA: total omega-3 PUFA ratios ever
reported in apparently healthy children. The findings of
this research could be the basis for future omega-3 LC-
PUFA intervention studies in Zimbabwe. The techniques
learnt for LC-PUFA analysis could the basis of technol-
ogy transfer to Zimbabwe.
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